SS 45 - GU 10: Biomarker Breakthroughs in Prostate Cancer

Presentations

• 10:30am - 10:40am PT

  Testosterone Recovery post Androgen Depletion Therapy in Intermediate Risk Prostate Cancer Patients. Does a Higher Dose of Radiotherapy Impact on Survival? Long-Term Data from a Phase III Trial

  Speaker: Abdenour Nabid, MD - CHUS, Sherbrooke
• 10:40am - 10:50am PT

  Validation of Six Androgen Production, Uptake and Conversion Genes (APUC-6) in the ECOG-ACRIN E3805 CHAARTED Prostate Cancer Trial

  Speaker: Phuoc Tran, MD, PhD - University of Texas MD Anderson Cancer Center, Houston
• 10:50am - 11:00am PT

  Hallmark Interferon-Alpha Response Analysis in Localized Prostate Cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, 9902, 0126, and 0521 Clinical Trials

  Speaker: Adam Olson, MD, MS - UPMC Hillman Cancer Center, Pittsburgh
• 11:00am - 11:10am PT

  Genomic Classifier and Multimodal AI Biomarker in Localized Prostate Cancer: Two Sides of the Same Coin

  Speaker: Kosj Yamoah, MD, PhD - H Lee Moffitt Cancer Center & Research Institute, Tampa
• 11:10am - 11:20am PT

  Predictive Role of Tumor Fraction and Copy Number Alteration Burden in mCRPC Patients Receiving Tandem Actinium-Lutetium Radionuclide Therapy

  Speaker: Mariam Amghar, PhD - German Cancer Research Center (DKFZ), Heidelberg
• 11:20am - 11:30am PT

  Influence of HSD3B1 Genotype on Prostate Cancer Outcomes following Definitive Radiation Therapy with Androgen Deprivation Therapy: A Retrospective Analysis of the Million Veterans Program

  Speaker: Kylie Morgan, BS - UCSD Health, La Jolla
• 11:30am - 11:40am PT

  Discussant

  Speaker: Alan Dal Pra, MD - University of Miami - Sylvester Comprehensive Cancer Center, Miami